Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
1.
Arq. gastroenterol ; 51(2): 84-89, Apr-Jun/2014. tab, graf
Article in English | LILACS | ID: lil-713585

ABSTRACT

Context Gastric mucosa-associated lymphoid tissue (MALT) lymphoma is clearly associated with Helicobacter pylori gastritis and can be cured with anti- H pylori therapy alone. The presence of t(11;18)(q21;q21) translocation is thought to predict a lower response rate to anti- H pylori treatment. Objectives To study the presence of t(11;18)(q21;q21) genetic translocation and its clinical impact in low-grade gastric MALT lymphoma Brazilian patients. Methods A consecutive series of eight patients with gastric MALT lymphoma were submitted to gastroscopy, endoscopic ultrasound, histopathological examination, H pylori search and RT-PCR-based methodology. All patients received anti-H pylori treatment. Eradicated patients were followed-up every 3-6 months for 2 years. Results Eight patients were studied. All patients had tumor involvement restricted to the mucosa or submucosa and seven patients had low-grade gastric MALT lymphoma. All infected patients achieved H pylori eradication. Histological tumor regression was observed in 5/7 (71%) of the low-grade gastric MALT lymphoma patients. The presence of t(11;18)(q21;q21) translocation was found in 4 (57%) of these patients; among them only two had histological tumor regression following H pylori eradication. Conclusions RT-PCR is a feasible and efficient method to detect t(11;18)(q21;q21) translocation, being carried out in routine molecular biology laboratories. The early detection of such translocation can be very helpful for better targeting the therapy to be applied to gastric MALT lymphoma patients. .


Contexto A patogênese do linfoma MALT (tecido linfoide associado à mucosa) gástrico, também conhecido como linfoma de zona marginal de células B, está claramente associada à gastrite por infecção pelo Helicobacter pylori e, a maioria desses tumores pode ser curada apenas com a erradicação da bactéria. A presença da translocação t(11;18)(q21;q21) tem sido identificada como a anomalia citogenética mais comum do linfoma MALT gástrico e sua presença pode prever uma menor taxa de resposta ao tratamento anti-H pylori. Objetivos Estudo da translocação genética t(11;18)(q21;q21) e seu impacto na evolução clínica de pacientes portadores de linfoma MALT gástrico de baixo grau. Métodos Uma série consecutiva de oito pacientes com linfoma MALT gástrico foi submetida à endoscopia digestiva, ultra-sonografia endoscópica, exame histopatológico, pesquisa do H pylori e metodologia rotineira de transcrição reversa seguida de reação em cadeia da polimerase (RT-PCR) utilizando primers específicos para API2-MALT1. Todos os pacientes receberam tratamento anti-H pylori e retratamento, quando necessário. Após a erradicação, exames endoscópicos foram realizados a cada 3-6 meses durante 2 anos para acompanhamento da evolução do tumor. Resultados Foram estudados oito pacientes (seis mulheres, idade média: 57 anos). Todos apresentavam à ecoendoscopia envolvimento tumoral restrito à mucosa ou submucosa com aparência endoscópica variável. A histologia mostrou que sete pacientes tinham linfoma MALT gástrico de baixo grau e um de alto grau. A erradicação do H pylori foi obtida em todos os pacientes, embora a bactéria não tenha sido identificada em um deles. Foi observada regressão histológica ...


Subject(s)
Adult , Aged , Female , Humans , Male , Middle Aged , Helicobacter pylori , Helicobacter Infections/complications , Lymphoma, B-Cell, Marginal Zone/genetics , Stomach Neoplasms/genetics , Translocation, Genetic/genetics , /genetics , /genetics , Helicobacter Infections/drug therapy , Lymphoma, B-Cell, Marginal Zone/microbiology , Neoplasm Grading , Reverse Transcriptase Polymerase Chain Reaction , Stomach Neoplasms/microbiology
3.
Gac. méd. Méx ; 143(3): 237-244, mayo-jun. 2007. ilus, tab
Article in Spanish | LILACS | ID: lil-568745

ABSTRACT

Se han realizado avances importantes en el entendimiento del linfoma de la zona marginal, (linfoma MALT), desde la primera descripción en 1983 por Peter Isaacson y Dennis Wright. Los linfomas MALT son un subgrupo de neoplasias de bajo grado que representan entre el 7 y el 8 % de todos los linfomas B, que se originan en sitios extraganglionares y presentan características clínico-patológicas propias. Se mantienen localizados por largos periodos de tiempo y sólo ocasionalmente se diseminan a otros órganos. Rara vez se originan de un MALT normal y aparecen en el MALT adquirido en el curso de alteraciones inflamatorias crónicas como en el síndrome de Sjögren o la infección por Helicobacter pylori. La erradicación de H. pylori puede producir regresión clínica del linfoma en un 75 % de los casos. Histológicamente presenta células B neoplásicas centrocitoides, células monocitoides y lesiones linfoepiteliales. El aparato digestivo, particularmente el estómago, está afectado en las dos terceras partes de los casos. Sin embargo, puede presentarse en otros órganos como glándulas salivales, pulmón, tiroides, anexos oculares y piel. Estudios genéticos han identificado tres traslocaciones cromosómicas específicas que son: t(11:18)(q21;q21), t(1;14)(p22;q32), y t(14;18)(q32;q21). A pesar de que estas traslocaciones afectan diferentes genes, comparten una vía oncogénica común que afecta al NFκB.


Significant advances in the understanding of marginal zone lymphoma since the first description in 1983 by Peter Isaacson and Dennis Wright have been noted. MALT lymphomas are a subgroup of low-grade B-cell lymphomas that arise from extranodal sites, comprising 7-8% of all B-cell lymphomas and displaying distinct clinicopathological characteristics. MALT lymphomas remain localized in the primary site for long periods of time and seldom disseminate unto other organs. These type of lymphomas infrequently arise in native MALT, but instead arise in MALT acquired in the course of chronic inflammatory disorders, such as Sjõgren's syndrome and Helicobacter pylori infection. Eradication of H. pylori produces a clinical regression of the lymphoma in about 75% of cases. The histological hallmarks of MALT lymphoma include neoplastic centrocyte-like B cells, cells resembling monocytoid cells and the presence of lymphoepithelial lesions. The gastrointestinal tract, particularly the stomach, include two-thirds of cases; however MALT lymphomas also occur in other organs such as salivary glands, lung, thyroid, ocular adnexa, breast and skin. Genetic studies have identified three chromosomal translocations specifically associated with MALT lymphomas that include: t(1l:18)(q21;q21), t(1;14)(p22;q32), and t(14;18)(q32;q21). Although these translocations involve different genes, they appear to share a common oncogenic pathway involving NFκB.


Subject(s)
Humans , History, 20th Century , Lymphoma, B-Cell, Marginal Zone/history , England , Lymphoma, B-Cell, Marginal Zone/genetics , Lymphoma, B-Cell, Marginal Zone/pathology
4.
Rev. chil. enferm. respir ; 22(2): 108-116, jun. 2006. ilus, tab
Article in Spanish | LILACS | ID: lil-436524

ABSTRACT

The present review describes the current classification of the pulmonary lymphoproliferative lesions as proposed by the WHO in 2004 with emphasis in the clinical picture and histopathological features. The definition of these entities includes the clinical picture, histopathology, immunohistochemistry and molecular features. The differential diagnosis of the most important entities is also briefly discussed


En el presente trabajo de revisión se describe la clasificación actual de las lesiones linfoproliferativas del pulmón propuesta por la OMS el año 2004 con énfasis en el cuadro clínico y los aspectos histopatológicos. La definición de estas entidades incluye cuadro clínico, histopatología, inmunohistoquímica y características moleculares. Se discute brevemente el diagnóstico diferencial de las formas más importantes


Subject(s)
Humans , Lung Diseases , Lung Neoplasms , Lymphoproliferative Disorders/classification , Diagnosis, Differential , Lymphomatoid Granulomatosis/genetics , Lymphomatoid Granulomatosis/immunology , Lymphomatoid Granulomatosis/pathology , Lymphoma, B-Cell/genetics , Lymphoma, B-Cell/immunology , Lymphoma, B-Cell/pathology , Lymphoma, B-Cell, Marginal Zone/genetics , Lymphoma, B-Cell, Marginal Zone/immunology , Lymphoma, B-Cell, Marginal Zone/pathology
SELECTION OF CITATIONS
SEARCH DETAIL